Mid-market transactions. Local expertise. Global reach.

PharmaX Solutions was sold to BioPhorum (

Sale of Allderma to Avia Pharma

Senn Chemicals AG (“Senn Chemicals”) announces the closing of the acquisition by Granules Peptides Private Limited, a wholly owned subsidiary of Granules India Limited (“Granules”) today April 10th, 2025. The acquisition enables Senn Chemicals to support its future as a leading peptide manufacturing company. Already back in February 2025, the Senn Family signed a share purchase agreement to transfer 100% of the shares of Senn Chemicals to Granules. Since its founding over 60 years ago by Guido Senn, Senn Chemicals has been a private, family-owned Swiss CDMO specialising in peptides. After a careful evaluation of potential ownership transfer options, the family decided to sell the company to Granules, a vertically integrated pharmaceutical company, focused on manufacturing and selling of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), and finished dosages (FDs). The Senn Chemicals brand and its site in Dielsdorf, Switzerland, will operate under Granules’ ownership, with a commitment to maintaining the company’s scientific excellence and customer focus. The acquisition brings Senn Chemical’s expertise in Liquid-Phase Peptide Synthesis (LPPS) and Solid-Phase Peptide Synthesis (SPPS), along with a strong CDMO business and established customer relationship, including innovators and brand owners across Pharma, Cosmetics, Amino Acid Derivatives (AAD) & theragnostic segments together with Granules’ market presence in India and the USA. Together with Senn Chemical’s expertise Granules gains the capabilities into high-growth peptide-based therapeutics. The acquisition aligns with Granules’ vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market, including GLP-1 receptor agonists and other next-generation therapeutics. Granules and Senn Chemicals have active in the development of GLP-1 based APIs, and more peptide-based APIs are planned to be developed using Senn Chemical’s R&D capabilities. The acquisition marks Granules’ foray into CDMO segments, leveraging Senn Chemical’s existing CDMO business and customer relationships, on back of its R&D and manufacturing platform. With this transaction, Granules will leverage Senn Chemical’s European presence and innovation-driven peptide platform to accelerate its CDMO expansion and meet the fast-growing demand for Amino Acid Derivative (AAD), peptide fragments, and peptide-based therapeutics. Senn Chemical’s presence in Europe provides access to a skilled R&D talent pool and regulated market clients, further strengthening Granules’ global footprint. Hoffmann & Partner (www.hoffmann-partner.com), the Basel-based M&A advisory firm specialising in life sciences, has acted as the exclusive M&A financial advisor in the transaction and advised the shareholders of Senn Chemicals with technical and industrial expertise.

offmann & Partner is pleased to announce that it has advised the shareholders of Nostos Genomics GmbH (“Nostos”) as M&A advisors in the successful acquisition by Limbus Medical Technologies GmbH (“Limbus”). Two leaders in genomic software are coming together – combining Limbus’ clinical-grade workflows with Nostos’ cutting-edge AI technology for variant interpretation.

We are pleased to announce the newly formed strategic partnership between the management of Aptco Group and Tilleghem.Aptco Group, an international specialist in scientific and laboratory equipment based in Belgium, will leverage this partnership to accelerate its growth ambitions through a focused buy-and-build strategy. VDP acted as advisor to the sellers.

Insentials joins forces with FG Bros and Eutopia. Insentials develops personalised nutrition and vitamin programs for women and sells dietary supplements. It was founded in 2021 by nutrition scientist Amandine De Paepe, following a career at Omega Pharma and the German pharmaceutical group Fresenius Kabi.To roll out the platform internationally, Amandine De Paepe is now bringing two international investors on board: the family investment holding of Ségolène Frère FG BROS and the French venture capital fund Eutopia, specialised in emerging brands. VDP acted as advisor to Insentials.

LB Research is a contract research organization located in Italy, founded on October 22nd, 2007. The staff is highly skilled and has long experience in the management of clinical trials; the main expertise is in Oncology. As of 30.06.2023 sales were about €4,7Mln. Current the Shareholders are evaluating the sale of the share capital.

Innovad, a portfolio company of IK Partners and a leading provider of animal nutrition and health solutions, has acquired Switzerland based Herbonis AG. Herbonis AG provides a plant-based source of the metabolic active form of Vitamin D, a unique and highly technical product with proven health benefits in poutry, swine and dairy. Hoffmann & Partner has advised the shareholders of Herbonis AG financially and strategically over many years. Dr. Urs Breitenstein, one of our founding partners, has been the chairman of this company for more than 5 years. He led the M&A activities in his role as chairman and leader of the M&A committee of the company.

BÜHLMANN Laboratories AG from Schönenbuch announces the completion of the acquisition by KLAR Partners Limited. Thanks to the acquisition, the company’s future is in safe hands. The strong global market positions of the BÜHLMANN Group will be further expanded. Since 1976, BÜHLMANN Laboratories AG, a privately owned Swiss SME, has been developing and marketing high-quality in-vitro diagnostics and distributing third-party molecular diagnostic products. The company distributes its own products through subsidiaries in Switzerland, Germany, France, Italy, Austria, the USA and Brazil, as well as through more than 60 qualified distributors worldwide. The owners signed a share purchase agreement at the beginning of May 2024 to transfer 100% of the shares of BÜHLMANN Laboratories AG and its subsidiaries (the BÜHLMANN Group) to KLAR Partners Limited. BÜHLMANN will remain a Swiss brand, the jobs and the Schönenbuch site will be retained after the acquisition, ensuring continuity for employees, customers and suppliers. The company philosophy with all the values that the BÜHLMANN Group is standing for to date will continue to be the fundamental guidelines for management. KLAR Partners is a European private equity firm focussing on investments in companies in the business services and industrial technology sectors. The companies in which KLAR invests have annual revenues of approximately EUR 50-500 million and are headquartered in the DACH, Scandinavia and Benelux regions. Together with the management of the BÜHLMANN Group, KLAR Partners will continue to invest in the BÜHLMANN Group and the Schönenbuch site and support the continuation of growth. As part of the succession planning, Laurent Collignon has been appointed as the new CEO. He will replace Dr Thomas Hafen, who has been playing a key role in shaping the company for the last 20 years. Thomas Hafen will leave BÜHLMANN AG at the end of September 2024, but will continue to be available to the company as a Senior Consultant. Hoffmann & Partner (www.hoffmann-partner.com), the Basel-based M&A advisory firm specialising in life sciences, has acted as the exclusive M&A financial advisor in the transaction and advised the shareholders of the BÜHLMANN Group with technical and industrial expertise.

Adviser to healthcare infrastructure specialists, Archus on the investment from BGF.